NCT01908621View on ClinicalTrials.gov

Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients.

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 20, 2013

Primary Completion Date

March 18, 2016

Study Completion Date

October 27, 2017

Conditions

Multiple Myeloma

Interventions

DRUG

G-CSF (filgrastim)

DRUG

Cytosine arabinoside + G-CSF (filgrastim)

Trial Locations (1)

44-101

Department of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Gliwice

All Listed Sponsors

lead

Maria Sklodowska-Curie National Research Institute of Oncology

OTHER

NCT01908621 - Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients. | Biotech Hunter | Biotech Hunter